The results with three TNBC lines (BP1, Hs578T, MDA-MB-231) and an aggressive triple negative inflammatory breast cancer line (SUM149), using molecular (siAHR, inducible shAHR, ectopic AHRR expression, and CRISPR-Cas9 gene editing) and pharmacological (AHR competitive inhibitors CH223191 and CB7993113) were completely consistent, i.e., AHR inhibition reduced all markers of tumor aggression. This evidence concerns the gene AHR and breast carcinoma.